Results of Annual General Meeting and changes to Innate Pharma’s governance and management team
June 26, 2017All proposed resolutions were voted according to management’s recommendations; Bpifrance Participations, represented by Maïlys Ferrere, and Pr. Jean-Charles Soria were appointed to the Supervisory...Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
June 15, 2017Oral presentation on the dose-escalation part of a Phase I trial at the International Conference on Malignant Lymphoma (ICML) in Lugano; IPH4102 was evaluated in elderly and heavily pretreated...Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody,from novo Nordisk A/S
June 2, 2017Anti-C5a receptor (C5aR) is a first-in-class clinical-stage monoclonal antibody (mAb) targeting myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment; Innate Pharma...Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017
May 23, 2017Proposals to appoint Supervisory board members and renew members’ mandates at the Annual General Meeting. Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual...IPH4102: Completion of the dose escalation part of the Phase I trial - Data to be presented at International Conference on Malignant Lymphoma in June 2017 in Lugano
May 22, 2017Complete safety results and updated clinical activity data will be presented at the ICML 2017 in Lugano in June; Preparation for cohort expansion part is ongoing. Innate Pharma SA (the “Company” -...First quarter 2017 report
May 15, 2017Cash, cash equivalents and financial assets of the Company amounted to €223.8 million* ; Additional clinical data expected later in 2017. Innate Pharma SA (the “Company” - Euronext Paris:...
